Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
87%
Multiple Myeloma
66%
Overall Survival
57%
Hematopoietic Cell
52%
Diseases
51%
Haemophilia A
49%
COVID-19
40%
Cell Transplantation
39%
Neoplasm
38%
Von Willebrand Disease
36%
Minimal Residual Disease
36%
Bleeding
36%
Von Willebrand Factor
35%
Diffuse Large B-Cell Lymphoma
32%
Progression Free Survival
31%
Arm
30%
Acute Leukemia
29%
Hazard Ratio
29%
Myeloma
26%
Randomized Controlled Trial
25%
Clinical Trial
24%
Quality of Life
22%
Systematic Review
22%
Pulmonary Embolism
20%
Thrombosis
20%
Leukemia
20%
Acute Lymphoblastic Leukemia
19%
Malignant Neoplasm
19%
Hodgkin's Lymphoma
19%
Cohort Analysis
19%
Cyclophosphamide
18%
Cancer
18%
Bleeding Disorder
18%
Adverse Event
18%
Myelodysplastic Syndrome
18%
Dexamethasone
17%
Meta-Analysis
16%
Infection
16%
Autologous Stem Cell Transplantation
15%
Gene Therapy
15%
Lenalidomide
15%
Blood Stasis
14%
Large-Cell Lymphoma
14%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Platelet
14%
Radiation Therapy
13%
Blood Clotting Factor 8
13%
Hematology
13%
Desmopressin
13%
Allogeneic Stem Cell Transplantation
12%
Polyethylene Terephthalate
12%
Hematologic Malignancy
12%
Positron Emission Tomography-Computed Tomography
12%
B-Cell Chronic Lymphocytic Leukemia
11%
Graft Versus Host Reaction
11%
Conditioning
11%
Haemophilia B
11%
T Cell
11%
Rituximab
10%
Non-Relapse Mortality
10%
Biological Marker
10%
Bortezomib
10%
Breast Cancer
10%
Oncology
9%
Patient with Hemophilia
9%
Fluorodeoxyglucose F 18
9%
Hematopoiesis
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
B Cell
9%
Health Care Cost
9%
Daratumumab
9%
Vitamin K Antagonist
9%
COVID-19 Vaccination
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
9%
Endothelial Cell
9%
Venetoclax
9%
Hemostat
9%
Positron Emission Tomography
9%
Next Generation Sequencing
9%
D-Dimer
9%
Chimeric Antigen Receptor T-Cell
9%
Acute Myelogenous Leukemia
8%
Fibrinolysis
8%
Patient-Reported Outcome
8%
Anticoagulation
8%
Retrospective Study
8%
Circulating Tumor Cell
8%
Odds Ratio
8%
Precursor
8%
Idiopathic Thrombocytopenic Purpura
8%
Risk Stratification
8%
International Prognostic Index
8%
Pharmacokinetics
8%
Cumulative Incidence
8%
Myelofibrosis
7%
Immunotherapy
7%
Acute Pulmonary Embolism
7%
Erythrocyte
7%
Computer Assisted Tomography
7%
Survival Rate
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
59%
Multiple Myeloma
52%
Diseases
50%
Haemophilia A
45%
Overall Survival
44%
Pharmacokinetics
35%
Progression Free Survival
32%
Bleeding
28%
Chemotherapy
27%
Neoplasm
26%
Von Willebrand Factor
26%
Clinical Trial
26%
Adverse Event
24%
Dexamethasone
24%
Remission
24%
Von Willebrand Disease
24%
Minimal Residual Disease
23%
Randomized Controlled Trial
22%
Diffuse Large B Cell Lymphoma
20%
Cyclophosphamide
19%
Malignant Neoplasm
19%
Myelodysplastic Syndrome
18%
Cohort Study
16%
Daratumumab
15%
Blood Clotting Factor 8
14%
Lenalidomide
14%
Acute Leukemia
14%
Thrombosis
14%
Lung Embolism
13%
Myeloma
12%
Coronavirinae
12%
Infection
12%
Large Cell Lymphoma
12%
Rituximab
12%
Biological Marker
12%
Pomalidomide
12%
Haemophilia B
11%
Chimeric Antigen Receptor
11%
Leukemia
11%
Anemia
11%
Antivitamin K
10%
Bortezomib
10%
Fibrinogen
10%
Chronic Lymphatic Leukemia
10%
Hodgkin Disease
9%
Acute Lymphoblastic Leukemia
9%
Blood Stasis
9%
Polyethylene Terephthalate
9%
Desmopressin
9%
Venous Thromboembolism
9%
Brain Ischemia
8%
Anticoagulant Agent
8%
Blood Clotting Factor 9
8%
Cerebrovascular Accident
8%
Cytarabine
7%
Graft Versus Host Reaction
7%
Fibrinolytic Agent
7%
Cytokine Release Syndrome
7%
Bleeding Disorder
7%
Frailty
7%
Breast Cancer
6%
SARS Coronavirus
6%
Blood Clotting Factor 8 Concentrate
6%
Placebo
6%
Alteplase
6%
Neutropenia
6%
D Dimer
6%
Survival Rate
5%
Thrombin
5%
Doxorubicin
5%
Monotherapy
5%
Hematologic Malignancy
5%
Fludarabine
5%
Venetoclax
5%
Side Effect
5%
Phase III Trials
5%
Congestive Heart Failure
5%
Event Free Survival
5%
Immunology and Microbiology
Myeloid
100%
Multiple Myeloma
71%
Hematopoietic Cell
64%
Overall Survival
54%
B Cell
40%
Cell Transplantation
37%
Progression Free Survival
31%
Cyclophosphamide
29%
Daratumumab
26%
T Cell
25%
Dexamethasone
23%
COVID-19
19%
Blood Plasma
17%
Conditioning
17%
Graft-Versus-Host Disease
16%
Arm
16%
Lenalidomide
15%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Allogeneic Stem Cell Transplantation
14%
Hematopoiesis
12%
Next Generation Sequencing
10%
Precursor
10%
Immunoglobulin Producing Cell
10%
Rituximab
9%
Lineages
9%
Pomalidomide
8%
Secretion (Process)
8%
Cord Blood Stem Cell Transplantation
8%
Transcriptomics
8%
Recurrence Free Survival
8%
Allele
8%
Chronic Graft Versus Host Disease
8%
Natural Killer Cell
8%
Positron Emission Tomography
8%
Factor VIII
8%
Circulating Tumor Cell
8%
Neutrophil
8%
Acute Graft Versus Host Disease
7%
Stem Cell
7%
Platelet
7%
Weibel Palade Body
7%
Chimeric Antigen Receptor T-Cell
7%
Immunotherapy
7%
Tyrosine
7%
Drug Megadose
7%
Fibrinolysis
7%
Autologous Stem Cell Transplantation
7%
Gene Mutation
6%
CD38
6%
RNA Sequence
6%
Stem Cell Transplant
6%
Bispecific Antibody
6%
Positron Emission Tomography-Computed Tomography
6%
Mesenchymal Stem Cell
6%
Epstein Barr Virus
6%
Macrophage
6%
Stem Cell Transplantation
6%
Gene Expression Assay
6%
Hematopoietic Stem Cell Transplantation
6%
Metabolic Tumor Volume
6%
Cytokine Release Syndrome
6%
Immune Response
6%
Umbilical Cord Blood
6%
Immunocompetent Cell
5%
Survival Rate
5%
Sickle Cell
5%
CCAAT Enhancer Binding Protein Alpha
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Cytokine
5%
B Cell Maturation Antigen
5%
Gene Expression
5%
Enhancer Region
5%
Hemocyte
5%
Colony Forming Cell
5%
Allograft
5%
Thrombin
5%
Zebra Fish
5%
Mouse Model
5%
Karyotype
5%
Cytotoxic T-Cell
5%
Cell Maturation
5%
Lymph Node
5%